Intraperitoneal application of the CDK6/IKZF1/IKZF3-degrading PROTAC YKL-06-102 at a maximal applicable dosage of 5 mg/kg per day (due to low solubility) significantly delayed tumor growth as compared to control treated mice, yet the effect was not better than pomalidomide or palbociclib alone, likely due to lower bioavailability in vivo (Supplementary Fig. 11). The gene discussed is CDK6; the disease is neoplasm.